Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer

Journal of the National Cancer Institute

Volumn 89, Issue 13, 1997, Pages 932-938

  Schildkraut, Joellen M ^a   Bastos, Eugenia ^a   Berchuck, Andrew ^b  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OVARY CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

EID: 0030979632     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.13.932     Document Type: Article

References (33)

1. Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect 1987; 73:35-51.
2. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650-5.
3. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711-6.
4. Joly DJ, Lilienfeld AB, Diamond EL, Bross I. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 1974;99:190-209.
5. Hildreth NG, Kelsey JL, LiVolsi VA, Fischer DB, Holford TR, Mostow ED, et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 1982;114:398-405.
6. Franceschi S, La Vecchia C, Helmrich SP, Mangioni C, Tognoni G, Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol 1982;115: 714-9.
7. Rosenberg L, Shapiro S, Stone D. Epithelial ovarian cancer and combination oral contraceptives. JAMA 1982;247:3210-2.
8. Weiss NS, Lyon JL, Liff JM, Vollmer WM, Daling JR. Incidence of ovarian cancer in relation to the use of oral contraceptives. Int J Cancer 1981; 28:669-71.
9. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184-203.
10. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1212-20.
11. Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983; 117:128-39.
12. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.
13. Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis [published erratum appears in Science 1990;249:1487]. Science 1990;249:970-1.
14. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-21.
15. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
16. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
17. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of p53 epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
18. Soussi T, Caron de Fromentel C, Mechali M, May P, Kress M. Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene 1987;1:71-8.
19. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993;85:1513-9.
20. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1204-11.
21. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, et al. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 1994;52: 232-6.
22. Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, et al. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992;40:1047-51.
23. Banks L, Matlashewski G, Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159:529-34.
24. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC Jr, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993;81:643-50.
25. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994;12:64-9.
26. Jones PA, Buckley JD, Henderson BE, Ross RK, Pike MC. From gene to carcinogen: a rapidly evolving field in molecular epidemiology. Cancer Res 1991;51:3617-20.
27. Sommer SS. Mutagen test [letter]. Nature 1990;346:22-3.
28. Berchuck A, Havrilesky L, Elbendary A, Bast RC Jr. Pathogenesis of ovarian cancer. J Soc Gynecol Invest 1994;1:181-90.
29. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
30. Amos CI, Shaw GL, Tucker MA, Hartge P. Age at onset for familial ovarian cancer. JAMA 1992;269:1896-9.
31. Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol 1992;80:19-26.
32. Cramer DW, Harlow BL, Willett WC, Welch WR, Bell DA, Scully RE, et al. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet 1989;2;66-71.
33. Cramer DW, Welch WR, Hutchison GB, Willett W, Scully RE. Dietary animal fat in relation to ovarian cancer risk. Obstet Gynecol 1984;63:833-8.